Athersys Future Hinges on Stem Cell Stroke Study Results – TheStreet.com
TheStreet.com |
Athersys Future Hinges on Stem Cell Stroke Study Results
TheStreet.com The company's stock price plunged last April when MultiStem, the stem cell therapy, failed to benefit ulcerative colitis patients. The MultiStem stroke study is Athersys' best and perhaps last chance for redemption. Athersys shares were trading around … Great Timing For Athersys, Other Stem Cell Companies Amidst Improving … |
